SCHEMBL10116183

SCHEMBL10116183

Cc1ccc(NC(=O)c2ccc(NS(=O)(=O)C(C)(C)C)cc2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.67
RAB9A P51151 4/20 0.67
MEN1 O00255 6/20 0.59
KMT2A Q03164 6/20 0.59
LMNA P02545 3/20 0.58
ALDH1A1 P00352 2/20 0.58
HPGD P15428 1/20 0.58
MAPT P10636 5/20 0.57
SMN1; SMN2 Q16637 3/20 0.57
MAPK1 P28482 1/20 0.52
SNCA P37840 1/20 0.51
CYP1A2 P05177 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2C9 P11712 1/20 0.51
KDM4E B2RXH2 3/20 0.50
NAMPT P43490 2/20 0.50
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
MCL1 Q07820 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10116298 0.96 NPC1 (0.61) NPC1RAB9AMEN1KMT2ALMNA
SCHEMBL10116240 0.94 MEN1 (0.55) NPC1RAB9AMEN1KMT2ALMNA
SCHEMBL10116238 0.88 KDM4E (0.65) NPC1RAB9AMEN1KMT2ALMNA
SCHEMBL10116194 0.88 MEN1 (0.65) NPC1RAB9AMEN1KMT2ALMNA
SCHEMBL10116182 0.88 KMT2A (0.57) NPC1RAB9AMEN1KMT2ALMNA
SCHEMBL10116397 0.87 KMT2A (0.49) NPC1RAB9AMEN1KMT2ALMNA
SCHEMBL10114513 0.87 MEN1 (0.61) NPC1RAB9AMEN1KMT2ALMNA
SCHEMBL10116191 0.87 NPC1 (0.66) NPC1RAB9AMEN1KMT2ALMNA
SCHEMBL10116235 0.87 MEN1 (0.52) NPC1RAB9AMEN1KMT2ALMNA
SCHEMBL10114489 0.85 TRPV1 (0.68) NPC1RAB9AMEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8115027-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2012-02-14 US disclosed
US-8115027-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2012-02-14 US disclosed
US-20110039802-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2011-02-17 US disclosed
US-20100292500-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2010-11-18 US disclosed
US-20100292500-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2010-11-18 US disclosed
US-7781461-B2 NPY Y5 antagonist KAWANISHI YASUYUKI 2010-08-24 US disclosed
US-7781461-B2 NPY Y5 antagonist KAWANISHI YASUYUKI 2010-08-24 US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 US disclosed
US-20070015762-A1 NPY Y5 antagonist KAWANISHI YASUYUKI 2007-01-18 US disclosed
US-20070015762-A1 NPY Y5 antagonist KAWANISHI YASUYUKI 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015762-A1 NPY Y5 antagonist NPY5R, NPY1R, NPY2R NPC1 1435/4885RAB9A 3699/4885MEN1 2876/4885
US-20100292500-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R NPC1 1353/4885RAB9A 3651/4885MEN1 2932/4885
US-20110039802-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R NPC1 1462/4885RAB9A 3820/4885MEN1 2926/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.